SCHEMBL6159694

SCHEMBL6159694

CC(C)(C)OC(=O)[C@H]1C[C@H]1C1CCN(Cc2ccccc2)C1

nearest known ligand 0.47

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 1/20 0.44
JAK1 P23458 1/20 0.44
KMT2A Q03164 2/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
NPFFR1 Q9GZQ6 1/20 0.42
NPFFR2 Q9Y5X5 1/20 0.42
BCHE P06276 4/20 0.42
ACHE P22303 3/20 0.42
BACE1 P56817 2/20 0.42
SCN4A P35499 2/20 0.42
MEN1 O00255 1/20 0.42
MAOB P27338 1/20 0.42
MCHR1 Q99705 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6159700 1.00 JAK2 (0.44) JAK2JAK1KMT2AL3MBTL1NPFFR1
SCHEMBL6160797 1.00 JAK2 (0.44) JAK2JAK1KMT2AL3MBTL1NPFFR1
SCHEMBL28943257 0.81 SCN4A (0.55) KMT2AL3MBTL1SCN4AMEN1
SCHEMBL6159416 0.81 JAK2 (0.53) JAK2JAK1KMT2AMEN1
SCHEMBL6159410 0.81 JAK2 (0.53) JAK2JAK1KMT2AMEN1
SCHEMBL6161940 0.81 JAK2 (0.53) JAK2JAK1KMT2AMEN1
SCHEMBL3642479 0.79 JAK2 (0.56) JAK2JAK1KMT2AMEN1
SCHEMBL16963755 0.79 JAK2 (0.56) JAK2JAK1KMT2AMEN1
SCHEMBL2050353 0.78 MEN1 (0.57) KMT2ABCHEACHEMEN1
SCHEMBL993829 0.77 CCR5 (0.58) JAK2JAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6949662-B2 Cis-substituted aminocyclopropane derivative DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2005-09-27 US disclosed
EP-0919553-B1 cis-SUBSTITUTED AMINOCYCLOPROPANE DERIVATIVES DAIICHI SEIYAKU CO (JP) 2005-03-02 EP disclosed
US-20020183523-A1 Cis-substituted aminocyclopropane derivative DAIICHI PHARMACEUTICAL CO., LTD 2002-12-05 US disclosed
US-6462040-B1 MICROBIOCIDES; BACTERIOCIDES; ANTIPROTOZOA AGENTS; QUINOLONE ANTIBIOTICS; SIDE EFFECT REDUCTION; ANTIBIOTIC-RESISTANT BACTERIA INCLUDING STAPHYLOCCOCUS; VETERINARY MEDICINE DAIICHO PHARMACEUTICAL CO., LTD. (JP) 2002-10-08 US disclosed
US-6391889-B2 POTENT ANTIMICROBIAL ACTIVITY ON BROAD RANGE OF MICROORGANISMS, E.G., STAPHYLOCOCCUS, GRAMPOSITIVE BACTERIA AND QUINOLONE ANTIBIOTIC RESISTANCE; SIDE EFFECT REDUCTION; NONTOXIC DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2002-05-21 US disclosed
US-20020052502-A1 Cis-substituted aminocyclopropane derivative DAIICHI PHARMACEUTICAL CO., LTD. 2002-05-02 US disclosed
US-20020002182-A1 CIS-SUBSTITUTED AMINOCYCLOPROPANE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2002-01-03 US disclosed
EP-0919553-A1 cis-SUBSTITUTED AMINOCYCLOPROPANE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 1999-06-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020052502-A1 Cis-substituted aminocyclopropane derivative SLC11A2, MYD88, ARG1 JAK2 3101/4885JAK1 3801/4885KMT2A 4480/4885
US-20020002182-A1 CIS-SUBSTITUTED AMINOCYCLOPROPANE DERIVATIVES PHOSPHO1, CCR2, ECH1 JAK2 3401/4885JAK1 4119/4885KMT2A 1309/4885
US-20020183523-A1 Cis-substituted aminocyclopropane derivative SLC11A2, MYD88, ARG1 JAK2 3101/4885JAK1 3801/4885KMT2A 4480/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.